CA
NZ
UK
AU
IND
US
Faeth Therapeutics, Inc. (NASDAQ: FTH) revealed disappointing earnings figures, recording an EPS of $-28.79 for the period ending June 30, significantly missing the consensus estimate of $-0.63. This stark deviation from expectations raises concerns about the company's financial health as it continues to develop …
Fresenius Medical Care AG (OTC: FMCQF) reported a strong 23% increase in income for the second quarter of 2026, demonstrating effective management of its operational strategies. Despite this favorable performance, shares climbed only 3.3% to $51.44, reflecting mixed market sentiment. In comparison, the company …
Galera Therapeutics, Inc. has officially concluded its merger with Obsidian Therapeutics, restructuring its ownership and issuing approximately 730,057 shares of common stock to its former shareholders. The transaction culminated on August 3, 2026, when the merger agreements were executed, marking a new chapter for …
Gilead Sciences, Inc. reported second quarter 2026 revenues of $7.8 billion, marking a 10% increase compared to the previous year. This performance was boosted by substantial growth in its HIV product sales and a solid increase in royalties and contracts. The consistent revenue trajectory …
Henry Schein, Inc. reported a quarterly earnings per share (EPS) of $1.27 for the period ending June 30, 2026, surpassing analyst expectations of $1.26. This represents a notable indicator of the company's financial health amid a competitive environment. Year-to-date, HSIC shares have seen a …
Henry Schein, Inc. (NASDAQ: HSIC) reported second-quarter earnings, achieving an EPS of $1.27 for the period ending June 30, 2026, which marginally exceeded the consensus estimate of $1.26. This quarter's results underscore the company’s strong operational performance, particularly useful as it navigates transitions in …
Hepion Pharmaceuticals announced the completion of a private placement that sold 61,100,000 common shares at $0.05 per share, delivering $3,055,000 in gross proceeds. Simultaneously, the company issued warrants for an equal number of shares, each exercisable at $0.06 for the next five years. The …
Erasca, Inc. (NASDAQ: ERAS) shares gained 3.6% to $18.49, approaching a significant deadline for investors involved in a securities fraud class action lawsuit. The law firm Berger Montague is advising investors who acquired Erasca stock between January 14, 2025, and April 26, 2026, to …
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) has appointed Danka Radosavljevic as Chief Operating Officer, a position expected to enhance the company's operational effectiveness. Radosavljevic, who brings five years of experience as Executive Vice President at Eton, will earn an annual salary of $520,800 plus an …
This growth comes as Exagen continues to capitalize on its AVISE CTD testing solutions, which have helped identify autoimmune diseases with greater efficiency. The company’s performance also stands out when compared to the consensus estimate of a $-0.19 EPS, as it reported an EPS …
Please wait processing your request...